CareDx, Inc (NASDAQ:CDNA) Shares Sold by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. decreased its position in shares of CareDx, Inc (NASDAQ:CDNA) by 3.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,817 shares of the company’s stock after selling 1,973 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in CareDx were worth $610,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Lazard Asset Management LLC lifted its stake in CareDx by 32.0% during the 1st quarter. Lazard Asset Management LLC now owns 3,225 shares of the company’s stock valued at $119,000 after acquiring an additional 782 shares during the period. Point72 Hong Kong Ltd acquired a new position in CareDx during the first quarter valued at $131,000. Cetera Advisor Networks LLC boosted its holdings in CareDx by 61.2% in the first quarter. Cetera Advisor Networks LLC now owns 7,510 shares of the company’s stock valued at $278,000 after purchasing an additional 2,850 shares during the last quarter. Royal Bank of Canada grew its position in CareDx by 127.6% during the 2nd quarter. Royal Bank of Canada now owns 8,430 shares of the company’s stock worth $71,000 after purchasing an additional 4,726 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in CareDx during the 1st quarter worth about $312,000.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an “overweight” rating and issued a $15.00 target price on shares of CareDx in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $13.50.

CareDx Stock Performance

Shares of NASDAQ CDNA opened at $8.28 on Thursday. The company has a market capitalization of $428.74 million, a PE ratio of -2.34 and a beta of 1.42. The company’s fifty day moving average price is $9.69 and its 200 day moving average price is $9.16. CareDx, Inc has a 1 year low of $4.80 and a 1 year high of $12.93.

CareDx (NASDAQ:CDNA) last posted its earnings results on Wednesday, February 28th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($1.97). CareDx had a negative return on equity of 51.40% and a negative net margin of 67.88%. The firm had revenue of $65.57 million for the quarter, compared to analysts’ expectations of $63.66 million. During the same period in the previous year, the company earned ($0.34) earnings per share. The company’s revenue was down 20.4% compared to the same quarter last year. On average, equities analysts expect that CareDx, Inc will post -1.59 EPS for the current year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.